The findings suggest that modulation of the TLR7 pathway may offer a novel therapeutic approach to treat anemia associated with Rps14 deficiency and other MDS‐related conditions, highlighting the potential of imiquimod as a therapeutic agent [30]. Here, RPS14 is linked to anemia.